Nanocan Therapeutics Corporation is an early-stage biotechnology company developing novel drug-delivery nanotechnology for more precise and targeted treatment of cancer and respiratory diseases. More precise local treatment can unlock local immune-driven potential and significantly reduce the risk of side effects. Through our partnerships with leading academic research institutions, we are rapidly developing new shorter and efficient combination therapies to help improve the lives of patients and improve global access to care.